New data presented at ASH 2020 reinforces the benefit/risk profile of fixed-duration Polivy plus bendamustine and MabThera/Rituxan in patients with relapsed or refractory diffuse large B-cell lymphoma

Basel, 07 December 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced longer-term data from the pivotal phase Ib/II GO29365 study, including data from a single-arm extension cohort of 106 additional patients, which show the benefit of Polivy ® (polatuzumab vedotin) plus bendamustine and MabThera®/Rituxan® (rituximab) (BR) in people with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), who are not eligible for stem cell transplant. Updated data from the randomised cohort (n=80) show that with longer follow-up (48.9 months) a complete response (CR) rate of 42.5% (n=17/40) was maintained in patients following completion of treatment with Polivy plus BR, compared to 17.5% (n=7/40) with BR alone, indicating responses to the Polivy regimen were durable. No new or delayed safety signals were reported. Furthermore, n ew data from an extension cohort showed a CR rate of 38.7% (n=41/106) with Polivy plus BR. These results, which were presented as a poster (Abstract #3020) at the all-virtual 62nd American Society of Hematology (ASH) Annual Meeting and Exposition on 5-8 December 2020, further support the clinical be nefit this Polivy-based combination brings to patients with this aggressive disease.“Despite recent advances, treatment options are needed that can improve survival outcomes, enhance convenience, and support a good quality of life for patients with relapsed or refractory diffuse large B-cell lymphoma,” said Levi Garraway, M.D., Ph.D., Roche’...
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news